A Randomized Trial of Liposomal Paclitaxel plus Cisplatin as First-line Therapy for Advanced Non-small Cell Lung Cancer
Chinese Journal of Lung Cancer, 04/19/2012
Yang X et al. – The effects of liposomal paclitaxel plus cisplatin (LP) and Paclitaxel plus cisplatin (TP) as first–line therapies for NSCLC are similar. However, peripheral neuritis in the LP arm is significantly lower than in the TP arm.